Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Test de l'ajout de la radiothérapie au traitement habituel (immunothérapie avec ou sans chimiothérapie) pour les patients atteints d'un cancer du poumon non à petites cellules de stade IV et PD-L1 négatif

17 novembre 2026 mis à jour par: National Cancer Institute (NCI)

Un essai randomisé de phase II/III sur la thérapie systémique basée sur l'immunothérapie moderne avec ou sans SBRT pour le cancer du poumon non à petites cellules avancé PD-L1 négatif

This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.

Aperçu de l'étude

Description détaillée

PRIMARY OBJECTIVE:

I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.

SECONDARY OBJECTIVES:

I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.

II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.

III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).

QUALITY OF LIFE (QOL) OBJECTIVE:

I. To assess the health-related QOL in both treatment arms.

CORRELATIVE SCIENCE OBJECTIVE:

I. To evaluate changes in the peripheral immune microenvironment between the arms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.

Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.

After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.

Type d'étude

Interventionnel

Inscription (Estimé)

427

Phase

  • Phase 2
  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Arizona
      • Phoenix, Arizona, États-Unis, 85054
        • Mayo Clinic Hospital in Arizona
    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Berkeley, California, États-Unis, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Duarte, California, États-Unis, 91010
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, États-Unis, 92618
        • City of Hope at Irvine Lennar
      • Lancaster, California, États-Unis, 93534
        • City of Hope Antelope Valley
      • Marysville, California, États-Unis, 95901
        • Fremont - Rideout Cancer Center
      • Modesto, California, États-Unis, 95355
        • Memorial Medical Center
      • Napa, California, États-Unis, 94558
        • Providence Queen of The Valley
      • Sacramento, California, États-Unis, 95817
        • University of California Davis Comprehensive Cancer Center
      • South Pasadena, California, États-Unis, 91030
        • City of Hope South Pasadena
      • Truckee, California, États-Unis, 96161
        • Gene Upshaw Memorial Tahoe Forest Cancer Center
      • Upland, California, États-Unis, 91786
        • City of Hope Upland
    • Colorado
      • Colorado Springs, Colorado, États-Unis, 80909
        • UCHealth Memorial Hospital Central
      • Colorado Springs, Colorado, États-Unis, 80920
        • Memorial Hospital North
      • Fort Collins, Colorado, États-Unis, 80524
        • Poudre Valley Hospital
      • Fort Collins, Colorado, États-Unis, 80528
        • Cancer Care and Hematology-Fort Collins
      • Greeley, Colorado, États-Unis, 80631
        • UCHealth Greeley Hospital
      • Loveland, Colorado, États-Unis, 80538
        • Medical Center of the Rockies
    • Delaware
      • Millville, Delaware, États-Unis, 19967
        • Beebe South Coastal Health Campus
      • Newark, Delaware, États-Unis, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, États-Unis, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, États-Unis, 19971
        • Beebe Health Campus
    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20010
        • MedStar Washington Hospital Center
    • Florida
      • Aventura, Florida, États-Unis, 33180
        • UM Sylvester Comprehensive Cancer Center at Aventura
      • Clearwater, Florida, États-Unis, 33756
        • Morton Plant Hospital
      • Coral Gables, Florida, États-Unis, 33146
        • UM Sylvester Comprehensive Cancer Center at Coral Gables
      • Deerfield Beach, Florida, États-Unis, 33442
        • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
      • Miami, Florida, États-Unis, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami, Florida, États-Unis, 33176
        • UM Sylvester Comprehensive Cancer Center at Kendall
      • Plantation, Florida, États-Unis, 33324
        • UM Sylvester Comprehensive Cancer Center at Plantation
      • Tampa, Florida, États-Unis, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
      • Winter Haven, Florida, États-Unis, 33881
        • Winter Haven Hospital
    • Georgia
      • Newnan, Georgia, États-Unis, 30265
        • CTCA at Southeastern Regional Medical Center
      • Savannah, Georgia, États-Unis, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Idaho
      • Boise, Idaho, États-Unis, 83712
        • Saint Luke's Cancer Institute - Boise
      • Fruitland, Idaho, États-Unis, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, États-Unis, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, États-Unis, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Twin Falls, Idaho, États-Unis, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Northwestern University
      • Chicago, Illinois, États-Unis, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, États-Unis, 60612
        • University of Illinois
      • Danville, Illinois, États-Unis, 61832
        • Carle at The Riverfront
      • DeKalb, Illinois, États-Unis, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, États-Unis, 62526
        • Decatur Memorial Hospital
      • Effingham, Illinois, États-Unis, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, États-Unis, 62401
        • Carle Physician Group-Effingham
      • Geneva, Illinois, États-Unis, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, États-Unis, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, États-Unis, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Harvey, Illinois, États-Unis, 60426
        • Ingalls Memorial Hospital
      • Lake Forest, Illinois, États-Unis, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Mattoon, Illinois, États-Unis, 61938
        • Carle Physician Group-Mattoon/Charleston
      • New Lenox, Illinois, États-Unis, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • O'Fallon, Illinois, États-Unis, 62269
        • HSHS Saint Elizabeth's Hospital
      • Orland Park, Illinois, États-Unis, 60462
        • University of Chicago Medicine-Orland Park
      • Rockford, Illinois, États-Unis, 61114
        • UW Health Carbone Cancer Center Rockford
      • Springfield, Illinois, États-Unis, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, États-Unis, 62702
        • Springfield Clinic
      • Springfield, Illinois, États-Unis, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, États-Unis, 61801
        • Carle Cancer Center
      • Warrenville, Illinois, États-Unis, 60555
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Crown Point, Indiana, États-Unis, 46307
        • UChicago Medicine Northwest Indiana
    • Iowa
      • Ames, Iowa, États-Unis, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, États-Unis, 50010
        • McFarland Clinic - Ames
      • Ankeny, Iowa, États-Unis, 50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Clive, Iowa, États-Unis, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, États-Unis, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Creston, Iowa, États-Unis, 50801
        • Greater Regional Medical Center
      • Des Moines, Iowa, États-Unis, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, États-Unis, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, États-Unis, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, États-Unis, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Waukee, Iowa, États-Unis, 50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
      • West Des Moines, Iowa, États-Unis, 50266
        • Mercy Medical Center-West Lakes
      • West Des Moines, Iowa, États-Unis, 50266
        • The Iowa Clinic PC
    • Kentucky
      • Lexington, Kentucky, États-Unis, 40536
        • University of Kentucky/Markey Cancer Center
      • Lexington, Kentucky, États-Unis, 40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
    • Maine
      • Sanford, Maine, États-Unis, 04073
        • MaineHealth Cancer Care Center of York County
      • Scarborough, Maine, États-Unis, 04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland, Maine, États-Unis, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton, Michigan, États-Unis, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Brighton, Michigan, États-Unis, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, États-Unis, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Canton, Michigan, États-Unis, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, États-Unis, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Chelsea, Michigan, États-Unis, 48118
        • Chelsea Hospital
      • Flint, Michigan, États-Unis, 48503
        • Hurley Medical Center
      • Flint, Michigan, États-Unis, 48503
        • Genesys Hurley Cancer Institute
      • Kalamazoo, Michigan, États-Unis, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, États-Unis, 49007
        • Bronson Methodist Hospital
      • Lansing, Michigan, États-Unis, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, États-Unis, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac, Michigan, États-Unis, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Pontiac, Michigan, États-Unis, 48341
        • Michigan Healthcare Professionals Pontiac
      • Saginaw, Michigan, États-Unis, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, États-Unis, 48601
        • MyMichigan Medical Center Saginaw
      • Tawas City, Michigan, États-Unis, 48764
        • MyMichigan Medical Center Tawas
      • West Branch, Michigan, États-Unis, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Ypsilanti, Michigan, États-Unis, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Duluth, Minnesota, États-Unis, 55805
        • Miller-Dwan Hospital
      • Minneapolis, Minnesota, États-Unis, 55415
        • Hennepin County Medical Center
      • Robbinsdale, Minnesota, États-Unis, 55422
        • North Memorial Medical Health Center
      • Saint Cloud, Minnesota, États-Unis, 56303
        • Coborn Cancer Center at Saint Cloud Hospital
      • Saint Paul, Minnesota, États-Unis, 55101
        • Regions Hospital
    • Missouri
      • Cape Girardeau, Missouri, États-Unis, 63703
        • Saint Francis Medical Center
      • Farmington, Missouri, États-Unis, 63640
        • Parkland Health Center - Farmington
      • Rolla, Missouri, États-Unis, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Sainte Genevieve, Missouri, États-Unis, 63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield, Missouri, États-Unis, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, États-Unis, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, États-Unis, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, États-Unis, 63128
        • Mercy Hospital South
      • Sullivan, Missouri, États-Unis, 63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Bozeman, Montana, États-Unis, 59715
        • Bozeman Health Deaconess Hospital
    • New York
      • Buffalo, New York, États-Unis, 14263
        • Roswell Park Cancer Institute
      • Lake Success, New York, États-Unis, 11042
        • Northwell Health/Center for Advanced Medicine
      • New York, New York, États-Unis, 10019
        • Mount Sinai West
      • New York, New York, États-Unis, 10029
        • Mount Sinai Hospital
      • New York, New York, États-Unis, 10011
        • Mount Sinai Chelsea
      • New York, New York, États-Unis, 10075
        • Lenox Hill Hospital
      • New York, New York, États-Unis, 10065
        • Manhattan Eye Ear and Throat Hospital
      • Oswego, New York, États-Unis, 13126
        • Upstate Cancer Center at Oswego
      • Oswego, New York, États-Unis, 13126
        • Upstate Cancer Center Radiation Oncology at Oswego
      • Syracuse, New York, États-Unis, 13210
        • State University of New York Upstate Medical University
      • Syracuse, New York, États-Unis, 13215
        • SUNY Upstate Medical Center-Community Campus
      • Syracuse, New York, États-Unis, 13210
        • Upstate Cancer Center at Hill Radiation Oncology
      • Verona, New York, États-Unis, 13478
        • Upstate Cancer Center at Verona
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Duke University Medical Center
      • Raleigh, North Carolina, États-Unis, 27609
        • Duke Cancer Center Raleigh
      • Winston-Salem, North Carolina, États-Unis, 27157
        • Wake Forest University Health Sciences
    • Ohio
      • Akron, Ohio, États-Unis, 44304
        • Summa Health System - Akron Campus
    • Oklahoma
      • Lawton, Oklahoma, États-Unis, 73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, États-Unis, 73120
        • Mercy Hospital Oklahoma City
    • Oregon
      • Gresham, Oregon, États-Unis, 97030
        • Legacy Mount Hood Medical Center
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health and Science University
      • Portland, Oregon, États-Unis, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Tualatin, Oregon, États-Unis, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Chadds Ford, Pennsylvania, États-Unis, 19317
        • Christiana Care Health System-Concord Health Center
      • Danville, Pennsylvania, États-Unis, 17822
        • Geisinger Medical Center
      • Hershey, Pennsylvania, États-Unis, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Lewisburg, Pennsylvania, États-Unis, 17837
        • Geisinger Medical Oncology-Lewisburg
      • Reading, Pennsylvania, États-Unis, 19605
        • Penn State Health Saint Joseph Medical Center
      • Wilkes-Barre, Pennsylvania, États-Unis, 18711
        • Geisinger Wyoming Valley/Henry Cancer Center
    • South Carolina
      • Charleston, South Carolina, États-Unis, 29425
        • Medical University of South Carolina
    • Texas
      • Amarillo, Texas, États-Unis, 79106
        • The Don and Sybil Harrington Cancer Center
    • Virginia
      • Richmond, Virginia, États-Unis, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, États-Unis, 23298
        • VCU Massey Comprehensive Cancer Center
      • Tappahannock, Virginia, États-Unis, 22560
        • VCU Health Tappahannock Hospital
    • Washington
      • Vancouver, Washington, États-Unis, 98686
        • Legacy Salmon Creek Hospital
      • Vancouver, Washington, États-Unis, 98684
        • Legacy Cancer Institute Medical Oncology and Day Treatment
      • Walla Walla, Washington, États-Unis, 99362
        • Providence Saint Mary Regional Cancer Center
    • West Virginia
      • Charleston, West Virginia, États-Unis, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
    • Wisconsin
      • Ashland, Wisconsin, États-Unis, 54806
        • Northwest Wisconsin Cancer Center
      • Eau Claire, Wisconsin, États-Unis, 54701
        • Marshfield Medical Center-EC Cancer Center
      • La Crosse, Wisconsin, États-Unis, 54601
        • Gundersen Lutheran Medical Center
      • La Crosse, Wisconsin, États-Unis, 54601
        • Mayo Clinic Health System-Franciscan Healthcare
      • Marshfield, Wisconsin, États-Unis, 54449
        • Marshfield Medical Center-Marshfield
      • Minocqua, Wisconsin, États-Unis, 54548
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, États-Unis, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, États-Unis, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, États-Unis, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Rice Lake, Wisconsin, États-Unis, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, États-Unis, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Waukesha, Wisconsin, États-Unis, 53188
        • UW Cancer Center at ProHealth Care
      • Weston, Wisconsin, États-Unis, 54476
        • Marshfield Medical Center - Weston

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
  • PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
  • For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
  • Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
  • Age >= 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
  • No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
  • No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
  • No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
  • >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
  • No prior allogeneic tissue/solid organ transplant
  • No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
  • No current pneumonitis or history of non-infectious pneumonitis that required steroids
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
  • No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
  • No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
  • Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
  • No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
  • No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
  • No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Platelet count >= 100,000/mm^3
  • Calculated (Calc.) creatinine clearance >= 45 mL/min
  • Total bilirubin =< 1.5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A (immunotherapy, +/- chemotherapy)

Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.

Ancillary studies

Autres noms:
  • Évaluation de la qualité de vie

Undergo blood sample collection

Autres noms:
  • Collecte d'échantillons biologiques
  • Spécimen biologique collecté
  • Collecte de spécimens
  • Collection d'échantillons

Given IV

Autres noms:
  • Anti-Anticorps Monoclonal Antigène-4 Associé aux Lymphocytes T Cytotoxiques
  • BMS-734016
  • Ipilimumab biosimilaire CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Undergo ECHO

Autres noms:
  • Échocardiographie
  • CE

Undergo PET

Autres noms:
  • Imagerie médicale, Tomographie par émission de positrons
  • ANIMAUX
  • TEP-scan
  • Scan de tomographie par émission de positrons
  • Tomographie par émission de positrons
  • PT
  • Tomographie par émission de positrons (procédure)

Given IV

Autres noms:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilaire CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • PAS 206
  • Nivolumab Biosimilaire ABP 206
  • BCD-263
  • Nivolumab biosimilaire BCD-263
  • BMS936558
  • ONO4538

Undergo tissue biopsy

Autres noms:
  • Bx
  • BIOPSIE_TYPE
  • Biopsie
Expérimental: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)

Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.

Ancillary studies

Autres noms:
  • Évaluation de la qualité de vie

Undergo blood sample collection

Autres noms:
  • Collecte d'échantillons biologiques
  • Spécimen biologique collecté
  • Collecte de spécimens
  • Collection d'échantillons

Given IV

Autres noms:
  • Anti-Anticorps Monoclonal Antigène-4 Associé aux Lymphocytes T Cytotoxiques
  • BMS-734016
  • Ipilimumab biosimilaire CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010

Undergo CT

Autres noms:
  • TDM
  • CHAT
  • Scanner
  • Tomographie axiale informatisée
  • Tomographie assistée par ordinateur
  • Tomodensitométrie
  • tomographie
  • Tomographie axiale informatisée (procédure)
  • Tomodensitométrie (TDM)
  • Scan de chat diagnostique
  • Type de service de scan de chat diagnostique

Undergo MRI

Autres noms:
  • IRM
  • Résonance magnétique
  • Balayage d'imagerie par résonance magnétique
  • Imagerie Médicale, Résonance Magnétique / Résonance Magnétique Nucléaire
  • M
  • Imagerie IRM
  • Imagerie RMN
  • NMRI
  • Imagerie par résonance magnétique nucléaire
  • Imagerie par résonance magnétique (IRM)
  • IRMs
  • Imagerie par résonance magnétique (procédure)
  • IRM structurelle

Undergo ECHO

Autres noms:
  • Échocardiographie
  • CE

Undergo PET

Autres noms:
  • Imagerie médicale, Tomographie par émission de positrons
  • ANIMAUX
  • TEP-scan
  • Scan de tomographie par émission de positrons
  • Tomographie par émission de positrons
  • PT
  • Tomographie par émission de positrons (procédure)

Given IV

Autres noms:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab biosimilaire CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • PAS 206
  • Nivolumab Biosimilaire ABP 206
  • BCD-263
  • Nivolumab biosimilaire BCD-263
  • BMS936558
  • ONO4538

Undergo radiation therapy

Autres noms:
  • Radiothérapie du cancer
  • ENERGY_TYPE
  • Irradier
  • Irradié
  • Irradiation
  • Radiation
  • Radiothérapie, SAI
  • Radiothérapie
  • RT
  • Thérapie, Radiation
  • Type d'énergie

Undergo tissue biopsy

Autres noms:
  • Bx
  • BIOPSIE_TYPE
  • Biopsie

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS) (Phase II)
Délai: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years

Will be performed on an intent-to-treat (ITT) basis.

From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
Overall survival (OS) (Phase III)
Délai: From randomization and death of all causes, assessed up to 5 years

Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status.

From randomization and death of all causes, assessed up to 5 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Qualité de vie
Délai: Jusqu'à 5 ans
Jusqu'à 5 ans
PFS
Délai: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years

Assessed per Response Evaluation Criteria in Solid Tumors (RECIST).

From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
Objective response rate (ORR)
Délai: Up to 5 years

Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates.

Up to 5 years
Incidence of treatment-related adverse events
Délai: Up to 5 years

Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test.

Up to 5 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Christine M Bestvina, Alliance for Clinical Trials in Oncology

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 octobre 2022

Achèvement primaire (Estimé)

12 décembre 2030

Achèvement de l'étude (Estimé)

12 décembre 2030

Dates d'inscription aux études

Première soumission

16 juin 2021

Première soumission répondant aux critères de contrôle qualité

16 juin 2021

Première publication (Réel)

18 juin 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

17 novembre 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NCI-2021-06042
  • U10CA180821 (Subvention/contrat des NIH des États-Unis)
  • NCI-2021-06042 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
  • A082002 (Autre identifiant: CTEP)
  • A082002 (Autre identifiant: Alliance for Clinical Trials in Oncology)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner